Management of Polycystic Ovary Syndrome in India

Sonia Malik, Kuldeep Jain¹, Pankaj Talwar¹, Sudha Prasad¹, Bharti Dhorepatil¹, Gouri Devi¹, Ashok Khurana¹, Vandana Bhatia¹, Nomita Chandiok², Alka Kriplani², Duru Shah², Geeta Sinha², Jyoti Unni², Madhuri Patil², Meeta Singh², Phagun Shah², Ratnabali Chakraborty², SM Bhattacharya, Siddarth Chatterjee², Sukumar Barik³, Rama Vaidya³, Subhash Kumar Wangnoo⁴, Ambrish Mithal⁴, Mohd. Ashraf Ganie⁴, Binayak Sinha⁴, Jayashree Gopal⁴, Waman Khadilkar⁵, Rahul Nagpal⁶, V. K. Khanna⁶, Nitin Verma⁶, Ahmed Zaheer⁶, Bindu Sthalekar⁶, Latika Arya⁷, Niti Khunger⁷, Rekha Sheth⁷, Dhiraj Bhatia⁷, Varun Duggal⁸, Anuradha Khadilkar⁹, Beena Joshi¹¹

President, Indian Fertility Society, Jawahar Lal Nehru Marg, New Delhi, ¹Publication group, Indian Fertility Society, Jawahar Lal Nehru Marg, New Delhi, India, ²Gynecologists, ³Reproductive Endocrinologist, ⁴Endocrinologists, ⁵Pediatric Endocrinologist, ⁶Pediatricians, ⁷Dermatologists, ⁸Physician, ⁹Ultrasonologist, ¹⁰Dietitian, ¹¹Scientist

INTRODUCTION

Polycystic Ovary Syndrome (PCOS) is one of the most common endocrinopathy affecting women. It has an unknown etiology and is recognized as a heterogeneous disorder that results in overproduction of androgens, primarily from the ovary, and is associated with insulin resistance (IR). The Rotterdam 2003 criteria defines PCOS as incidence of any two of the three key criteria, namely, oligoovulation and/or anovulation, excess androgen activity and polycystic ovaries (PCO). However, the terminology used in the context of PCOS needs to be revisited to reflect the actual clinical nature of PCOS.

Studies of PCOS in India carried out in convenience samples reported a prevalence of 3.7% to 22.5%, with 9.13% to 36% prevalence in adolescents only. The wide variation in prevalence might be due to heterogeneous presentation of symptoms, diagnostic criteria practiced, limitations in diagnosis, age groups, and ethnic populations studied. Therefore, it is essential to consider these factors before diagnosis and/or management is initiated. Further studies are needed to understand the dynamics in prevalence rates of PCOS across India. Although there is a paucity of data from large scale surveillance studies, the higher incidence of PCOS risk factors (high body mass index (BMI), IR) in India, suggests that the real extent of the problem might be currently underestimated.

The most common symptoms of PCOS can range from menstrual disorders, infertility, hyperandrogenemia to metabolic syndrome (MS). Elevated insulin levels due to IR may lead to development of PCOS by contributing to the underlying abnormalities seen in the hypothalamic-pituitary-ovarian axis. The resulting complex of physiological dysfunction produced by interrelated metabolic and hormonal factors, predisposes patients with PCOS to different complications like endometrial hyperplasia and cancer, cardiovascular disease (CVD), miscarriage, and acanthosis nigricans (AN). The complications add to the burden faced by patients, besides affecting social and emotional wellbeing, especially in adolescents, who are under the impression of being afflicted by a ‘disease’.

Efficient management of PCOS provides a prospective window of opportunity to avoid the risk of associated complications. Treatment is broadly aimed at tackling (IR), effects of hyperandrogenism, irregular menstruation, and infertility. However, given the complex nature of PCOS, tailoring treatment options to the needs of individual patients can be a difficult clinical exercise. Long-term risks of PCOS must be balanced against current acute needs of the patients like the desire for continued fertility and the need to ameliorate the cosmetic challenges associated with PCOS. Due to its heterogeneous nature, effective management of PCOS needs a sustained, multi-pronged strategy with inter-disciplinary expertise, based on strong evidentiary framework to guide the standardization of care. However, in contemporary clinical practice in India, successful interdisciplinary cross-linking of efforts is stymied by the lack of awareness about PCOS and guidelines addressing its management. Further, in view of the higher risk of PCOS in Indian women, and the relative lack of medical infrastructure to deal with the chronic outcomes of PCOS, effective, evidence-based treatment guidelines for India are an immediate necessity. The current good clinical practice recommendations (GCPR) are an effort to provide a comprehensive framework for addressing
issues relating to the management of PCOS in India. It is aimed at providing scientific evidence and well-balanced information on multi-disciplinary approach for the management of PCOS to health care providers in India.

**METHODOLOGY**

Systematic review of literature was conducted to provide the best possible evidence base for the GCPR. Existing guidelines, meta-analyses, systematic reviews, key cited articles relating to PCOS were reviewed by a group of doctors and recommendations relevant to Indian scenario were framed. The recommendations were discussed by an expert panel of gynecologists, physicians, ultrasonologists, endocrinologists, dermatologists, and pediatricians in a series of meetings. GCPR for each section of the guidelines were discussed and where there was little or no evidence, the panel relied on experience, judgment and consensus to make their recommendations. The current consensus GCPR are developed in accordance to the American Association of Clinical Endocrinologists (AACE) protocol for standardized production of clinical practice guidelines. Recommendations are based on clinical importance (graded as A: strongly recommended, B: suggested, and C: unresolved) coupled by four intuitive levels of evidence (1 = ‘at least one randomized controlled trial (RCT) or meta-analysis of RCTs’, 2 = ‘at least one non-randomized or non-controlled, prospective epidemiological study’, 3 = ‘cross-sectional or observational or surveillance or pilot study’ and 4 = ‘existing guideline or consensus expert opinion on extensive patient experience or review’).

**RISK FACTORS FOR THE ASSESSMENT OF PCOS**

**Current Evidence:**

Several risk factors are associated with the incidence of PCOS, but not all are causative or predisposing factors for PCOS. However, their presentation is indicative of the incidence of PCOS. Thus the risk factors included in the current section indicate the risk for PCOS diagnosis but not the etiological likelihood of disease development. A preliminary understanding of the clinical characteristics and medical history of the patients is an invaluable resource for assessing the risk of PCOS incidence.

**Biochemical risk factors**

BMI is a key risk factor associated with the incidence of PCOS (mean BMI: 29.3 ± 7.5 vs. 25.6 ± 5.8 kg/m², p < 0.001 in women with and without PCOS),[10,11] higher BMI has been implicated as an important indicative marker of PCOS status. In women with PCOS, changes in BMI during adolescence are positively associated with changes in waist circumference (p < 0.0001), low density lipoprotein-cholesterol (LDL-C) (p = 0.01), triglycerides (TG) (p = 0.008), and systolic blood pressure (SBP) (p = 0.002).[12] In adults, a BMI ≥ 23 kg/m² is considered overweight/obese,[13] whereas in adolescents BMI > 97.5th percentile for age and gender are regarded as overweight/obese.[14,15] In addition, development of clinical features of PCOS is often preceded by a history of weight gain,[16,17] and factors independently associated with BMI: higher energy intake and glycaemic index, low physical activity, smoking, alcohol intake.[18,19]

Development of IR and dysregulation of lipid metabolism are seen even in the early stages of PCOS.[19] Significantly higher IR (fasting serum insulin) is observed in patients with PCOS with apparently normal oral glucose tolerance test (OGTT).[20] Similarly, early signs of lipid metabolic dysregulation (elevated serum total cholesterol, TG and LDL-C levels and carotid intima-media thickness) were observed in age-matched patients with PCOS between 18-35 years.[19] Presence of family history of PCOS or diabetes or an inadequate lifestyle have also been shown to be important risk factors for incidence of PCOS [Figure 1].[21,22]

**Clinical risk factors**

Patients with normal menstrual cycle compared to patients with oligo/amenorrhea show significantly better metabolic parameters (BMI, fasting insulin, and Homeostasis Model Assessment- insulin resistance (HOMA-IR).[23] Due consideration to the patient’s demographic profile is important in determining the PCOS status of a patient, since the risk and presentation varies in different patient groups. In adolescent patients, the diagnostic criteria of PCOS based on the signs and symptoms often overlap with the characteristics of normal puberty. In adolescents and younger women with PCOS, primary risk factors include disturbances in periodicity/timing of menstrual cycle and chronic anovulation while, in older women obesity, IR, and metabolic disturbances are
Clinical hyperandrogenism
Oligo- or anovulation

Recommended diagnosis
Rotterdam

NIH
Ovarian size/morphology on ultrasound

Table 1. Diagnostic criteria for PCOS

<table>
<thead>
<tr>
<th>Category</th>
<th>Specific abnormality</th>
<th>Recommended diagnosis</th>
<th>NIH</th>
<th>Rotterdam</th>
<th>AE-PCOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Androgen status</td>
<td>Clinical hyperandrogenism</td>
<td>Hirsutism, acne, and central alopecia</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Biochemical hyperandrogenism</td>
<td>Increased total, bioavailable, or free serum testosterone levels</td>
<td>XX</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Oligo- or anovulation</td>
<td>Anovulation: frequent (&lt; 21 d) or infrequent (&gt; 35 d) bleeding intervals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mid-luteal progesterone test:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for anovulatory bleeding in</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>women with regular ovulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovarian appearance</td>
<td>Ovarian size/morphology on ultrasound</td>
<td>PCO morphology: presence of ≥ 12 follicles of 2-9 mm diameter and/or ovarian volume &gt; 10 mL without a cyst or dominant follicle &gt; 10 mm</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

PCOS: polycystic ovary syndrome; NIH: National Institute of Health; AE-PCOS: Androgen excess-polycystic ovary syndrome; PCO: Polycystic ovary.

Recommended on risk factors for assessment of PCOS

- It is recommended that Indian women showing at least one biochemical characteristic in conjunction with one clinical symptom should be considered for further evaluation for the likelihood of PCOS (Grade A, EL 3).

1. Biochemical characteristics: high BMI for overweight/obesity > 23 kg/m² for adults and > 97.5th percentile for age in adolescents, insulin resistance (acanthosis nigricans as clinical marker of insulin resistance), family history of diabetes or PCOS, obesity and inadequate lifestyle, any marker of lipid metabolic dysregulation (elevated serum total cholesterol, triglyceride and LDL-C levels),

2. Clinical symptoms: pubertal deviations (early or late), disturbances in periodicity/timing of menstrual cycle, presence of PCO and clinical signs of hyperandrogenism such as early acne or hirsutism, persistent severe acne, frequent relapse in acne, acne in facial ‘V’ area, persistent acne and hirsutism for more than two years

- In women suspected to have PCOS, it is recommended to screen and appropriately document all clinical and biochemical risk factors in the case history (Grade A, EL 4).

- It is recommended that patients who currently show either a clinical symptom or fit into a biochemical characteristic may be referred for further diagnosis when feasible or should be regularly monitored for appearance of other presentations of PCOS (Grade A, EL 4).

- It is recommended that individual patients with two or more clinical risk factors be subjectively assessed by the gynecologist and referred to an appropriate healthcare provider for further diagnosis of PCOS (Grade B, EL 4).

**DIAGNOSTIC CRITERIA FOR ADULTS AND ADOLESCENTS WITH PCOS**

The three main criteria for diagnosis of PCOS are androgen excess (AE), chronic anovulation, and presence of (PCO) [Table 1]. Initial, hyperandrogenism (clinical or biochemical) and anovulation along with recommendations for exclusion of other mimicking etiologies were common diagnostic criteria. The European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) sponsored Rotterdam group on PCOS introduced an extension to incorporate ovarian morphology (based on an ultrasonogram). The Rotterdam criteria proposed that a positive observation of two of the three criteria (AE, ovulatory dysfunction, or PCO) constituted a diagnosis for PCOS. A recent National Institute of Health (NIH)-sponsored workshop on PCOS endorsed the Rotterdam criteria for diagnosis of PCOS.
The diagnostic criteria proposed for diagnosis of PCOS are established in adults, and requires objective evaluation for diagnosis in adolescents.

**Current evidence**

**Androgen excess**

It is established using either clinical or biochemical determination of hyperandrogenism.\[2\]

**Biochemical hyperandrogenism**

Biochemical hyperandrogenism is a measure of androgen levels, determined by total, bioavailable, or free serum testosterone (T) levels.\[13,14\] In addition, the free androgen index (FAI=100 x [total testosterone/ Sex hormone-binding globulin]) is also widely used.\[10\] However, total serum T levels are considered more reliable and suitable for diagnosing androgens status.\[13,37\] Given the methodological challenges, variability in T levels during pubertal development,\[38\] and uncertainty in clinical practice\[39\] defining absolute values using local assays that are diagnostic of PCOS and/or to exclude other causes of hyperandrogenism is preferable. Further, since the physiological T levels alter with pharmacological agents used for induction of periods, diagnosis of AE should not be carried in these subjects.

**Clinical hyperandrogenism**

Clinical hyperandrogenism includes hirsutism, acne, and androgenic/central alopecia.\[2\]

A. **Hirsutism**: Hirsutism is the excessive growth of thick, dark terminal hair in women where hair growth is normally absent.
Disorder

Prolactin excess

Abnormal values

Thyrokinemia: If TSH > upper limit (0.5 mIU/L)
Hyperthyroidism: If TSH < lower limit (<0.1 mIU/L)
> Upper limit of normal
≥ 29 ng/mL
200-800 ng/dL

PCOS: Polycystic ovary syndrome, TSH: Thyroid stimulating hormone,
*To be done before 8 a.m.

Polycystic ovary

Polycystic ovary morphology as defined by ESHRE/ASRM consensus criteria is as at least one ovary with ≥ 12 follicles of 2–9 mm (between day 2-5 of cycle) or ovarian volume > 10 mL in the absence of a cyst or dominant follicle > 10 mm established with ultrasound examination of ovaries. It is also endorsed by the Rotterdam criteria and NIH. It is important to distinguish PCO from multi-follicular ovaries to make an appropriate diagnosis of PCO morphology. Multi-follicular ovaries contain larger (up to 10 mm diameter) and fewer (up to 6 each ovary) cysts, without hypertrrophic echogenic stroma. A study comparing sonographic ovarian morphology in Indian women with and without PCOS found that a combination of two-three sonographic criteria is required to improve the sensitivity of PCO diagnosis.

In normal adolescent physiology, presence of multi-follicular/PCO is a common feature that decreases with cycle regularity and requires strict interpretation of ultrasonography findings of PCO morphology. Since no well-defined cut-off values for determining the levels of anti-mullerian hormone (non-invasive test) exist, ultrasound examination of ovaries is recommended for the diagnosis of PCO morphology in adolescents. In adolescent girls with PCOS, obesity is common; magnetic resonance imaging (MRI) scanning is a more accurate modality to evaluate PCO in these adolescents.

On the other hand, ovarian volume and follicle number decrease from peak reproductive years to age > 40 years in normal as well as PCOS women. Therefore, diagnostic criteria with a combination of age, log ovarian volume, follicle number, and testosterone can be used to distinguish PCO morphology in women at menopausal stage.

Exclusion criteria for diagnosis of PCOS

PCOS is considered a diagnosis of exclusion. During the diagnosis of PCOS, it is important to screen all women to exclude other disorders like thyroid disease, prolactin excess and non-classical congenital adrenal hyperplasia, which mimic the symptoms of PCOS. Mild prolactinemia and subclinical hyperthyroidism are common features in patients with PCOS. Therefore a referral to specialist is required if excess values are reported for prolactin and thyroid stimulating hormone (TSH) T4 levels.

Minimal diagnosis of PCOS in adolescents

Since the three diagnostic criteria for PCOS defined by the guidelines were derived for adults, to establish the diagnosis of PCOS in adolescents, other biochemical and clinical estimations can be ordered by the consulting physician or gynecologist. However, it is essential to order use minimal tests possible to diagnose PCOS in adolescent subjects to avoid burden of tests.

Existing guidelines

The clinical practice guidelines from Endocrine society, USA PCOS Australian alliance, Australia, The RCOG, UK and SOGC, Canada endorse the Rotterdam criteria for the diagnosis of PCOS. However, all guidelines advocate that specific phenotypes leading to diagnosis of PCOS be documented in all research studies and clinical care.
**Recommendations for the diagnosis of PCOS in adults and adolescents**

- In women with PCOS, for the objective assessment of cutaneous manifestations such as hirsutism, acne and androgenic alopecia, Indian specific grading should be performed with appropriate scales and possibility of other etiologies should be excluded (Grade B, EL 3)

**Adults**

- In adult women, it is recommended that diagnosis of PCOS be made using the Rotterdam criteria, meeting two of the following three conditions: (Grade A, EL 4)
  - Androgen excess
  - Biochemical: serum total testosterone
  - Clinical: persistent acne, hirsutism, female pattern hair loss
  - Ovulatory dysfunction
  - Polycystic ovary
- Presentation of acanthosis nigricans with or without obesity is an additional diagnostic criterion for PCOS in adults and adolescents* (Grade B, EL 4).
- Mild prolactinemia and subclinical hypothyroidism are common in PCOS; referral to specialist should be made when indicated by prolactin or TSH, T4 levels (Grade B, EL 4)
- Determination of anti-mullerian hormone levels for diagnosis of PCO is not recommended in adult and adolescent women (Grade A, EL 4).
- In peri-menopausal and menopausal women with a clinical history of prolonged periods of androgen excess and oligomenorrhea during the reproductive years, additional evidence of PCO morphology, log ovarian volume, follicle number, and testosterone should be considered as a diagnosis of PCOS (Grade B, EL 3).

**Adolescents**

- In adolescents, presence of oligomenorrhea or amenorrhea beyond two years of menarche should be considered an early clinical sign of PCOS, followed by Rotterdam criteria (of adults) for diagnosis of PCOS (Grade B, EL 4).
  - Androgen excess
  - Biochemical: serum total testosterone
  - Clinical: acne, hirsutism, female pattern hair loss
  - Ovulatory dysfunction
  - PCO with strict interpretation of ultrasonography findings
- Minimal diagnosis of PCOS in adolescents should include 5 tests (Grade A, EL 4):
  - Serum total testosterone (cut off 60 ng/dl)
  - OGTT (at zero and two hours after 75 g glucose load)
  - Serum 17- hydroxy progesterone (assessed at 8 am)
  - Serum TSH
  - Serum prolactin levels
- For the diagnosis of PCOS in adolescents, serum LH, follicle stimulating hormone (FSH) and cortisol should be assessed as indicated (Grade B, EL 4).

*Healthcare provider should assess other signs of IR and MS

**MANAGEMENT OF PATIENTS WITH PCOS**

Management of PCOS stretches beyond the realm of symptomatic treatment and encompasses management of long-term consequences that have clinical and psychological effects on women with PCOS. Both non-pharmacological and pharmacological management strategies are crucial in overall management of PCOS. Because the three main characteristics of PCOS (hyperandrogenism, oligoovulation and IR) drive most of its long-term consequences, management approaches targeted at them may potentially provide improvement in all aspects of the syndrome.

**Non-pharmacological interventions for management of obesity and body weight in patients with PCOS**

Management of IR and obesity should be considered the first-line of treatment of PCOS. A meta-analysis reported improved levels of FSH, sex-hormone binding globulin, total T, androstenedione, FAI, and mFG score in women with PCOS as a result of lifestyle interventions (diet and physical activity); similar improvements in metabolic indicators were also reported.[63-65]

**Exercise**

**Current Evidence**

Studies on PCOS from India reported a prevalence rate of 37.5% to 62.5% for obesity in patients with PCOS. A family history of obesity is also associated with PCOS phenotype.[66] Obese women with PCOS have a higher incidence of characteristics of MS (hypertension, impaired glucose tolerance (IGT) and type 2 diabetes Mellitus (T2DM) as well as higher odds of irregular menstrual cycles and clinical hyperandrogenism than lean women with PCOS.[64] Despite lack of large RCTs, the benefits of physical activity (at least 150 minutes of per week) in improving metabolic status and reducing the incidence of diabetes in high risk groups of general population have been demonstrated in small controlled studies.[64,66]

In Indian adolescents with PCOS, compared to controlled (C) treatment with physical exercise, holistic yoga (Y) was found to significantly reduce the T levels (Y = -6.01, C = +2.61, p = 0.014), mFG score for hirsutism (Y = -1.14, C = +0.06, p = 0.002), and improved menstrual frequency (Y = 0.89, C = -0.49, p = 0.049).[70] Another RCT on adolescents with PCOS from India found significantly improved fasting insulin and glucose levels, HOMA-IR, and lipid values, independent of their anthropometric changes, with yoga practice compared to conventional physical exercise.[71]

**Existing guidelines**

Clinical practice guidelines from Endocrine society[29] and RCOG[31] suggest exercise therapy in the management of weight and obesity in PCOS.

**Recommendations on non-pharmacological management of PCOS: physical activity**

- In adults and adolescents with PCOS, daily strict physical activity sessions for at least 30 min/day or 150 min/week are recommended (Grade A, EL 4).

**Diet**

**Current evidence**

While the benefits of diet control on obesity and IR in PCOS have been widely reported, data from RCTs, especially in Indian women is limited. Women with PCOS have been reported to have higher prevalence of central obesity.[25] In women with PCOS and obesity, weight loss through diet control has been shown to improve pregnancy rates, normalize hyperandrogenemia,[64-73,74] improve...
insulin sensitivity, menstrual functions, and hirsutism\textsuperscript{[73,72]}

However, no PCOS-specific diet has been reported. Therefore, it is essential to consult a dietician for optimal weight management in women with PCOS. In patients with weight loss response after lifestyle modification + calorie-restricted diet as first-line therapy, weight neutral, insulin sensitizer drugs such as metformin can be used as second-line therapy.

Existing guidelines
The clinical practice guidelines from Endocrine society,\textsuperscript{[29]} RCOG\textsuperscript{[31]} and PCOS Australia alliance\textsuperscript{[59]} suggest using low calorie diet as first-line therapy for the management of obesity in PCOS.

Recommendations on non-pharmacological management of PCOS-dietary

- For the management of obesity in adults (BMI > 23 kg/m\textsuperscript{2}) and adolescents (BMI > 97.5\textsuperscript{th} percentile for age) with PCOS, it is recommended to follow lifestyle modifications in combination with healthy, balanced diet consisting of regular, calorie-restricted meals (Grade B, EL 4).
- In adult and adolescent women with PCOS, it is recommended to routinely screen for BMI and waist circumference as an index for increasing adiposity and development of hyperandrogenism (Grade A, EL 3).
- It is recommended to follow calorie restricted diet (low carbohydrate and fat, high protein) in consultation with a dietician and lifestyle modification as first-line therapy for at least 6 months, then add metformin as second-line therapy (Grade B, EL 4).

PHARMACOLOGICAL INTERVENTIONS FOR MANAGEMENT OF PATIENTS WITH PCOS

As discussed above, the choice of treatment in women with PCOS can be broadly categorized to treat the symptoms of menstrual irregularities (MI) and hyperandrogenism.

Menstrual irregularity

Current evidence

In women with MI, proliferation of endometrium can be inhibited using either cyclic progestin or combined oral contraceptives (COCs: estrogen + progestin). Low-dose COCs (< 50 mcg of estrogen in combination with a progestin) have been the mainstay of treatment for MI in patients with PCOS not willing to conceive. In order to reduce the risk of endometrial proliferative disorders, progestogen withdrawal bleeds are generally accepted as first-line therapy to ameliorate cycle regularity in women with PCOS. Three issues have to be considered while choosing a COC: type of progestin compound used, type of estrogen compound used (usually 30 mcg ethinyl estradiol [EE]), and dosage of progestin and estrogen compounds in combination.\textsuperscript{[76]}

Current evidences from India in the management of MI in women with PCOS are available on COCs with two progestin components- drospirenone and desogestrel. The effects of two COCs 3 mg drospirenone vs. 0.15 mcg desogestrel (in combination with 30 mcg EE) on MI in women with PCOS were compared for 6 month treatment period and 6 months post-treatment.\textsuperscript{[42]} Although patients from both groups achieved menstrual regularity during the treatment, higher proportion of patients from drospirenone group continued to have regular cycles (44.8%) than desogestrel group (17.2%) at 6 months post-treatment (p < 0.01). In another study, drospirenone group was effective in reducing the hirsutism score in patients with both MI and.\textsuperscript{[42]} Overall, drospirenone containing COCs are more efficient compared to desogestrel containing COCs because of its anti-androgenic effects on menstrual cycle regularity, lipid profile, Blood Pressure(BP), and hormonal profile.\textsuperscript{[42]} Besides drospirenone and desogestrel, other progestins commonly used in India for clinical practice, either as cyclic progestin or COCs, for the management of MI in women with PCOS include natural micronized progesterone, dienogest, nor-ethisterone and the levonorgestrel- intrauterine system (LNG-IUS).

The AE in women with PCOS is also linked to IR and consequent hyperinsulinemia,\textsuperscript{[77]} driving the use of insulin sensitizers such as metformin\textsuperscript{[78]} and thiazolidinediones\textsuperscript{[79]} in the management of PCOS. The effects of metformin on glucose homeostasis and improved cycle pattern are mainly attributed to increased insulin sensitivity.\textsuperscript{[80]} Metformin in combination with a low-dose anti-androgen (spironolactone) was more beneficial than either drug alone in improving MI in adult women with PCOS, presenting with oligo-/amenorrhea, hyperandrogenism and PCO morphology.\textsuperscript{[81,82]}

However, metformin monotherapy for six months resulted in regular menses within 4 months of treatment, but a consistent reversal towards pre-treatment conditions was observed within 3 months of metformin withdrawal.\textsuperscript{[83]} Adverse events such as vomiting, nausea, diarrhea, and hyperadrenergic symptoms were reported in patients taking metformin including drug withdrawal in subjects.\textsuperscript{[81]} Therefore the expert panel recommends against the use of metformin as first-line therapy for MI, but as second-line therapy with or without low-dose COCs, if COCs are not successful or tolerated.

The duration of metformin treatment for treatment of ovulatory dysfunctions in adolescents is not established due to very limited evidence from long-term studies and conflicting evidences from short-term studies. Therefore an extrapolation of evidence from studies conducted in adults may be required to recommend the use of metformin in adolescents. Use of spironolactone alone for the management of MI seems clinically inappropriate, since MI have been reported in 18% patients with low-dose spironolactone (50-100 mg daily) and in 70% patients with high-dose (200 mg daily).\textsuperscript{[84,85]} In an Indian study, polyuria (> 5%), abdominal pain, MI (> 10%), and dryness of mouth were reported in patients with PCOS taking spironolactone, and caused drug withdrawal in four subjects.\textsuperscript{[81]}
Existing guidelines
The ACOG recommends low-dose COCs as primary treatment option for improved MI and other menstrual disorders in women with PCOS. The clinical practice guidelines from Endocrine society[29] RCOG[31] and PCOS Australia alliance[30] also recommend use of hormonal contraceptives as first-line therapy for menstrual abnormalities of PCOS. The guidelines from Endocrine society[29] further recommend screening contraindications to COC use via established criteria set by ‘Centers for disease control and prevention (CDC)- US medical eligibility criteria for contraceptive use’.

Recommendations on management of menstrual irregularity in PCOS [Figure 2]

Adults
- In adults with PCOS showing menstrual irregularity, it is recommended to include progestogen withdrawal bleeds as first-line therapy till menopause to avoid the risk of endometrial proliferative disorders (Grade A, EL 4)
- In adults with PCOS who do not intend to conceive, it is recommended to use COCs (drospirenone and desogestrel as progestin component) for the management of menstrual irregularity (Grade A, EL 1). Drospirenone has been shown to be more beneficial than desogestrel in Indian conditions.
- In women with PCOS, metformin is not recommended as first-line therapy for the management of menstrual irregularity (Grade A, EL 4).
- In women with PCOS, spironolactone is not recommended for menstrual irregularity (Grade B, EL 4).
- In adults and adolescents with PCOS, if there is no improvement of menstrual irregularity with COCs or COCs are not tolerated, it is recommended to use insulin sensitizers such as metformin (with or without progestins), but not thiazolidinediones for the management of menstrual irregularity (Grade A, EL 2).

Adolescents
- In adolescents with PCOS, it is suggested to use low-dose COCs (with or without anti-androgenic progestins-drospirenone and desogestrel) for the management of MI (Grade A, EL 4).
- Between 12-16 years of age, low-dose COCs only to be used, for short period (up to 7 days).
- After 16 years, low-dose COCs to be used.
- Menstrual regularity: 4 cycles/year in adolescents of 12-16 years.
- In adults and adolescents with PCOS with menstrual irregularity and hirsutism, low-dose COCs are suggested (Grade A, EL 2).

Hyperandrogenism
Current evidence
Hirsutism, acne and androgenic alopecia are the clinical symptoms of hyperandrogenism observed in women with PCOS. The AE in women with PCOS is manifested as excessive terminal hair growth and acne.[87] A prevalence of 44.16% for hirsutism and AN and 20% for acne were observed in PCOS women from India.[137] Features of clinical hyperandrogenism-hirsutism (33.6% vs. 28%) as well as acne and oily skin (40.6% vs. 22.6%) were found to be significantly higher in obese women with PCOS than lean PCOS women.[54]

Management of hirsutism
Management of hyperandrogenism requires long-term and multi-dimensional treatment. This involves a combination of lifestyle modification, mechanical hair removal methods and pharmacological therapy for androgenic suppression.

Lifestyle modifications
A recent review comparing minimal or no treatment with lifestyle modifications (diet, exercise, behavioral or combined treatments) in patients with PCOS, reported improved body composition, hyperandrogenism and IR in women with PCOS.[18] Further, metformin + weight reduction therapy are reported to reduce IR and T levels in women with PCOS.[88]

Pharmacological therapy
As with menstrual cycles, COCs are first-line agents for pharmacologic treatment of hirsutism in women not willing to conceive.[76] COCs with anti-androgenic progestins such as cyproterone acetate (CPA), drospirenone, desogestrel are generally used for the management of hirsutism in women with PCOS. Parallel administration of direct (mechanical) hair removal methods ameliorates the condition and reduces the time required.

Treatment with two mg CPA was shown to significantly reduce mean FG scores from (14.3 to 5.7) after 12 weeks of therapy in women with PCOS.[93] In another study, two mg CPA + 35 mcg EE (for 48 consecutive cycles) demonstrated significant reduction of mFG score (mean FG score 10.4) in 73% subjects. [90] No significant side effects or patient withdrawal were reported during 48 cycles of therapy, probably due to considerable effects on hirsutism, complete remission of acne, excellent cycle regularity and endometrial control observed with EE/CPA.[90]

Evidence from India comparing COCs: CPA, desogestrel (deso), and drospirenone (dros) in women with PCOS reporting MI+hirsutism, found that CPA showed the strongest anti-androgen activities with significant decrease in mFG score (treatment difference: CPA -5.29, dros -2.12, deso -1.69) after 12 months of treatment.[91] In this study, very few patients reported adverse events: desogestrel group- bloatedness and sensation of weight gain, nausea and headache, rise of BP; CPA group- breast tenderness and absence of withdrawal bleeding in the pill-free week; drospirenone group- one patient with nausea, vomiting, and vertigo, another with altered liver function test. Studies on drospirenone (3 mg + 30 mcg EE)[92] and desogestrel (150 mcg + 30 mcg EE)[93] also demonstrated significant improvement in mFG score (4.6 vs. 6.4) compared to baseline.

In another evidence from India, compared to metformin, spironolactone demonstrated better improvement in hirsutism score (12.5 ± 4.9 and 12.9 ± 3.2 at baseline to 10.0 ± 3.3 and 8.7 ± 1.9, respectively) after 6 months therapy in women with PCOS reporting MI, hirsutism.[95] Whereas finasteride (5 mg/day), a 5α-reductase inhibitor, in comparison with CPA (25 mg/day on days 5-14) + EE (20 mcg/day on days 5-25) was equally effective in reducing mFG scores after 9 months of treatment.[89] However, due to the risk of teratogenicity (feminization of male infant) with their use,[95] the expert panel has recommended to cease the use at least 6 months before planned pregnancy. Therefore, spironolactone and finasteride can be used as second-line treatment for the management of hirsutism in patients with PCOS.
In addition to hormonal therapy, administration of insulin sensitizers can improve the hyperinsulinemic as well as hyperandrogenic state in women with PCOS. However, due to limited evidence on use of metformin in adolescents without established glucose intolerance, the expert panel recommends against its use in adolescents with PCOS. Further, lifestyle modification is better than metformin in improving hyperandrogenism, obesity and signs of IR. Therefore the expert panel recommends lifestyle modification as first-line therapy followed by metformin in adolescents and children. Metformin should be initiated in children only after a wait-period of two years post-menarche.

By virtue of the nature of hyperandrogenism, the source of androgen cannot be eliminated permanently, and evidence suggests that hyperandrogenism requires long-term therapy. Therefore, ideal time to stop the hormonal therapy for hyperandrogenism cannot be established.

**Risk of venous thromboembolism**

Use of different COCs with varying risks of venous thromboembolism (VTE) is reported in general population. However evidence in women with PCOS is inconsistent. A recent meta-analysis of trials using either COCs with anti-androgens, or metformin in women with PCOS found that thromboembolic episodes were not reported in any study. A cross-sectional analysis on a database (2003-2008, US women) observed that PCOS women were more likely to have thromboembolism than those without and reported a protective association (OR 0.8; 95% CI: 0.73-0.98) with use of COCs. Since there is lack of consistent data on diagnosis and management of VTE specific to PCOS, the expert panel has suggested ways to minimize the risks and maximize the benefits of COC use. It is essential to regularly monitor the risk and provide three months of pause after one year of COC regimen. Investigations used to monitor VTE risk in general population (such as using duplex ultrasonography for deep vein thrombosis and chest X-ray/ ventilation-perfusion scan/ CT pulmonary angiography for pulmonary embolism) can also be adopted in women with PCOS.

**Mechanical hair removal methods**

Apart from the pharmacological approaches to deal with hirsutism, temporary and permanent methods of hair removal/ reduction should also be used as first-line therapy for management of hirsutism in women with PCOS. Permanent methods of hair reduction therapy include electrolysis and photo epilation devices such as laser and intense pulsed light. In patients seeking permanent hair reduction therapy, it is essential to initiate pharmacologic therapy to minimize hair regrowth. Temporary hair removal methods such as depilation, epilation, and bleaching are effective in reducing facial hair growth in women with PCOS. In addition, topical treatment with eflornithine, an ornithine decarboxylase inhibitor approved by United states of food and drug administration (US-FDA), is also effective.

**Management of acne**

Management of acne needs careful selection of anti-acne agents according to clinical presentation and individual patient needs. Adjunctive therapies of topical applications along with hormone therapy should be used as first-line therapy for synergistic effects. Physical treatment methods (lesion removal, phototherapy) are also suggested for acne management.

**Topical applications**

Based on the clinical presentation of acne in individual patient, specific topical medication for mild and moderate acne, and maintenance therapy should be prescribed in consultation with dermatologist. Benzoyl peroxide, topical retinoids, and topical antibiotics are used as first-line treatment for acne management.

**Hormone therapy**

Hormone therapy is suggested as first-line therapy for androgenic acne in women with PCOS, SAHA syndrome, HAIRAN syndrome (hyperandrogenism, IR, AN), or cutaneous hyperandrogenism. The IAA consensus guideline further justifies hormonal therapy in refractory/difficult acne and in nodulocystic acne where isotretinoin is either contraindicated or inadequate. However, due to the multiple causes of acne vulgaris, evaluation of hormonal status is a prerequisite before initiating hormone therapy.

Treatment with two mg CPA (+35 mcg EE) for 12 cycles significantly reduced acne score in all 41% cases (at baseline), with improved facial acne by the end of third cycle and improved thorax and back acne by end of 6th cycle. Treatment with CPA/EE combination for 48 cycles demonstrated a complete recovery of various types of acne lesions (moderate 67%, severe 33% cases at baseline) in all subjects (100%) within 24 cycles of treatment. In a study conducted in Indian women with PCOS, CPA demonstrated numerically higher reduction in acne score (CPA -1.52, drospirenone -1.42, desogestrel -1.41) compared to other pills. CPA has been well studied as an androgen receptor blocking agent, effective in acne management in females. Higher doses of CPA have been reported to be more effective than lower dose to treat acne.

In another study, drospirenone (3 mg + 30 mcg EE) containing COC showed significant improvement in acne at six cycles (54.9% vs. 31.4%, p < 0.05) compared to baseline. Although EE/drospirenone was administered only for 6 months, the beneficial effects in reducing hyperandrogenic features of hirsutism and acne were maintained up to 12 months after treatment. No adverse effects were reported. Similarly, desogestrel (150 mcg) + EE 30 mcg also showed significant improvement in the incidence of acne (54.1% vs. 23.4%) in women with PCOS from India after 6 cycles of treatment. No adverse effects were reported up to one year with EE/desogestrel also.

The guidelines issued by IAA recommend hormonal therapy in patients presenting acne with symptoms of SAHA syndrome (with or without irregular cycles) or resistance to conventional therapy/ relapse after isotretinoin therapy along with altered endocrine function. Based on the consensus developed by IAA, hormone therapy with low-dose EE/CPA or high-dose CPA or spironolactone are specifically suggested.

In adolescents with PCOS, improvement in acne was observed with the use of oral contraceptives with anti-androgen activity. In a latest randomized cross-over trial, therapy with
Appendix Table 3. Summary of studies from India conducted with anti-androgen progestins for the management of hyperandrogenism

<table>
<thead>
<tr>
<th>Study author</th>
<th>Study details</th>
<th>Study end point summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhattacharya et al.</td>
<td>• Double-blind randomized clinical trial&lt;br&gt;• Effects of OCPs containing DSG 30/150 µg (n=56), CPA 55/2000 µg (n=56) and DRSP 30/3000 µg (n=57) in PCOS, after 6 and 12 months of therapy</td>
<td>Change in baseline at 6 months and 12 months&lt;br&gt;• mFG score: -2.09±3.29 and -5.29±5.88&lt;br&gt;• Acne: -0.48±1.18% and -1.42±1.27%&lt;br&gt;• FAI: -6.09±7.51 and -10.57±9.93&lt;br&gt;• T levels: -0.04±0.24 ng/mL and -0.03±0.42 ng/mL&lt;br&gt;• SHBG levels: 93.75±85.71 nmol/L and 142.91±60.71 nmol/L</td>
</tr>
<tr>
<td>Bhattacharya et al.</td>
<td>• Open label, single arm study&lt;br&gt;• Combination of DRSP 9mg vs EE 30mcg cyclically in the traditional (21±7) regimen&lt;br&gt;• n=51 (15-52 years)&lt;br&gt;• Evaluation at baseline and after six and twelve cycles of treatment</td>
<td>Baseline at 6 months and end point at 12 months&lt;br&gt;• FG score: 6.7±5.2 at 0 month, 4.8±3.1% at 6 months, 6.6±2.9 at 12 months, (P&lt;0.05)&lt;br&gt;• Acne: At 6 cycles 54.9% vs 31.4%, (P&lt;0.05) and at 12 cycles 54.9% vs 29.4%, (P&lt;0.05)&lt;br&gt;• T levels: 0.51±0.3 ng/mL at baseline, 0.30±0.1 ng/mL at 6 months, 0.28±0.16 ng/mL at 12 months&lt;br&gt;• SHBG levels: 31±15.9 nmol/L at baseline, 155.1±67.0 nmol/L at 6 months, 157.6±68.7 nmol/L at 12 months&lt;br&gt;• FAI: 6.4±5.2 at baseline, 0.9±1.1 at 6th month, 0.8±0.8 at 12th month</td>
</tr>
<tr>
<td>Bhattacharya et al.</td>
<td>• Randomized trial&lt;br&gt;• EE + DRSP vs DSG containing COCs&lt;br&gt;• n=60 (16-40 years)&lt;br&gt;• Study group-DRSP 9 mg + EE 30 mcg&lt;br&gt;• Control group-DSG 150 mcg + EE 30mcg, for 6 months and evaluation at 1,3 and 6 months during and post treatment</td>
<td>Change in baseline at 6 months and 12 months&lt;br&gt;• mFG score: -1.53±3.98 and -2.12±6.58&lt;br&gt;• Acne: -0.63±1.17% and -1.32±1.25%&lt;br&gt;• FAI: -5.27±2.22 and -7.89±9.13&lt;br&gt;• T levels: -0.04±0.28 ng/mL and -0.06±0.32 ng/mL&lt;br&gt;• SHBG levels: 97.52±94.55 nmol/L and 131.52±72.89 nmol/L</td>
</tr>
<tr>
<td>Bhattacharya et al.</td>
<td>• Double-blind randomized controlled trial&lt;br&gt;• Effects of OCPs containing DSG 30/150 µg (n=56), CPA 55/2000 µg (n=56) and DRSP 30/3000 µg (n=57) in PCOS, after 6 and 12 months of therapy</td>
<td>Change in baseline at 6 months and 12 months&lt;br&gt;• mFG score: -1.57±4.97 and -1.09±5.09&lt;br&gt;• Acne: -0.95±1.21% and -1.41±1.35%&lt;br&gt;• FAI: 5.13±8.72 and 5.58±9.15&lt;br&gt;• T levels: -0.09±0.22 ng/mL and -0.10±0.39 ng/mL&lt;br&gt;• SHBG levels: 76.05±79.41 nmol/L and 99.53±67.52 nmol/L</td>
</tr>
<tr>
<td>Desogestrel</td>
<td>• Double-blind randomized controlled trial&lt;br&gt;• Effects of OCPs containing DSG 30/150 µg (n=56), CPA 55/2000 µg (n=56) and DRSP 30/3000 µg (n=57) in PCOS, after 6 and 12 months of therapy</td>
<td>Change from baseline and 12 months&lt;br&gt;• FG score: 6.4±5.0 at baseline 4.6±3.6 at 6th month 3.7±3.4 at 12th month&lt;br&gt;• Acne reduced from 21% and 6%, (P&lt;0.0001)&lt;br&gt;• FAI: 8.±± 9.7 at baseline 1.1±1.1 at 6th month and 1.6±2.0 at 12th month&lt;br&gt;• SHBG levels: 31.03±22.12 nmol/L at baseline 141.9±78.72 nmol/L at 6th month and 183.4±75.3 nmol/L at 12th month (P&lt;0.0001)&lt;br&gt;• T levels: 0.94±0.2 ng/mL at base line, 0.34±0.2 ng/mL at 6th month and 0.37±0.2 ng/mL at 12th month</td>
</tr>
<tr>
<td>Bhattacharya et al.</td>
<td>• Open label, randomized study for 6 months&lt;br&gt;• Therapeutic effects DCG (150 mg) and EE (30 mg) combination pill for 12 months</td>
<td>Change from baseline and 12 months&lt;br&gt;• FG score: 6.4±5.0 at baseline 4.6±3.6 at 6th month 3.7±3.4 at 12th month&lt;br&gt;• Acne reduced from 21% and 6%, (P&lt;0.0001)&lt;br&gt;• FAI: 8.±± 9.7 at baseline 1.1±1.1 at 6th month and 1.6±2.0 at 12th month&lt;br&gt;• SHBG levels: 31.03±22.12 nmol/L at baseline 141.9±78.72 nmol/L at 6th month and 183.4±75.3 nmol/L at 12th month (P&lt;0.0001)&lt;br&gt;• T levels: 0.94±0.2 ng/mL at base line, 0.34±0.2 ng/mL at 6th month and 0.37±0.2 ng/mL at 12th month</td>
</tr>
<tr>
<td>Ganie et al.</td>
<td>• Open-label, randomized study for 6 months&lt;br&gt;• Efficacy of combination of low-dose spironolactone and metformin vs either drug alone, n=169&lt;br&gt;• Metformin n=56, spironolactone n=51, combination n=62&lt;br&gt;• Dose- metformin (1000 mg/d), spironolactone (50 mg/d)</td>
<td>Change from baseline and 12 months&lt;br&gt;• FG score: 6.4±5.0 at baseline 4.6±3.6 at 6th month 3.7±3.4 at 12th month&lt;br&gt;• Acne reduced from 21% and 6%, (P&lt;0.0001)&lt;br&gt;• FAI: 8.±± 9.7 at baseline 1.1±1.1 at 6th month and 1.6±2.0 at 12th month&lt;br&gt;• SHBG levels: 31.03±22.12 nmol/L at baseline 141.9±78.72 nmol/L at 6th month and 183.4±75.3 nmol/L at 12th month (P&lt;0.0001)&lt;br&gt;• T levels: 0.94±0.2 ng/mL at base line, 0.34±0.2 ng/mL at 6th month and 0.37±0.2 ng/mL at 12th month</td>
</tr>
</tbody>
</table>
Appendix Table 3: Continued

<table>
<thead>
<tr>
<th>Study author</th>
<th>Study details</th>
<th>Study end point summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ganie et al. 2004</td>
<td>• Open labelled and randomized controlled study</td>
<td>• The number of menstrual cycles in spironolactone from 6.6±2.1 at baseline, 9.0±1.9 at 3rd month and 10.2±1.9 at 6th month, (P=0.001)</td>
</tr>
<tr>
<td></td>
<td>• Efficacy of spironolactone (50 mg/d) vs metformin (1000 mg/d) n=82</td>
<td>• Metformin: 5.7±2.3/year at baseline, 7.4±2.6/year at 3rd month, 9.1±2.0/year at 6th month, (P=0.001)</td>
</tr>
<tr>
<td></td>
<td>• Metformin n=35 Spironolactone n=34</td>
<td>• FG score spironolactone:12.9±3.2 at baseline to 10.1±3.1, at 3rd month and 8.7±1.9 at 6th month, (P=0.054)</td>
</tr>
<tr>
<td>Vaswani N et al. 1990</td>
<td>• Randomized trial</td>
<td>• Metformin: 12.5±4.9 at baseline, 11.4±4.1at 3rd month and 10.0±3.3 at 6th month</td>
</tr>
<tr>
<td></td>
<td>• Relative efficacy of spironolactone vs cimetidine</td>
<td>• T values metformin: 83.9±45 ng/mL at baseline. 72.9±54 ng/mL at 3 months and 49.9±24.8 ng/mL at 6 months, (P=0.001)</td>
</tr>
<tr>
<td></td>
<td>• a=1.5 spironolactone (100 mg daily), n=14 cimetidine (1400 mg daily) cyclically for 12 weeks</td>
<td>• Spironolactone: 102.9±9.8 ng/mL at baseline, 55.9±28.8 ng/mL at 3 months and 55.9±28.8 ng/mL at 6 months, (P=0.001)</td>
</tr>
<tr>
<td>Kulshreshtha et al. 2012</td>
<td>• Effect of 6 months of therapy with metformin (an insulin sensitizer) and spironolactone on glucose tolerance, n=88</td>
<td>• Spironolactone: 73.3% in 11 acne patients</td>
</tr>
<tr>
<td></td>
<td>• n=42-metformin 1g daily</td>
<td>• Cimetidine: 42.8% in 6 acne patients</td>
</tr>
<tr>
<td></td>
<td>• n=46-spiroolactone 50-75 mg daily</td>
<td>• The response of acne vulgaris to spironolactone was superior to that of cimetidine and this difference was significant (P&lt;0.05)</td>
</tr>
</tbody>
</table>


mefloyxprogesterone acetate and CPA for four months each,[105] CPA significantly improved acne score and LH/FSH ratio.[105]

Due to the limited evidence on long-term use of COCs for hyperandrogenic features in adolescents, the expert panel suggested using COCs in adolescents based on the clinical presentation of acne, in consultation with a dermatologist.

A summary of studies conducted in India with COCs containing anti-androgen in progestins (cyproterone acetate, drospirenone, and desogestrel) for the management of hyperandrogenism features is presented in Appendix Table 3.

Management of alopecia

Although there is limited evidence on the management of alopecia, COCs and androgen blockers can be used to reduce alopecia. It is essential to determine and exclude etiologies that mimic alopecia. Ina study on alopecia in general population, CPA + EE demonstrated a marked improvement in alopecia (success rate: 55%).[106] In another study, CPA (for 6-9 months) demonstrated a marked reduction in hair loss, hair thinning, and seborrhea in androgenic feminine alopecia.[107]

Existing guidelines

The clinical practice guidelines from Endocrine society,[39] recommend use of hormonal contraceptives as first-line therapy for management of clinical features of hyperandrogenism such as hirsutism/acne in women with PCOS. The consensus guideline from IAA recommends the use of hormone therapy with low-dose EE/CPA or higher doses of CPA or spironolactone.[45]

Recommendations for management of Hyperandrogenism in PCOS

Hirsutism

- Following options can be used alone or in combination to suit individual patient needs and clinical requirements for the management of hirsutism:
  - In adult women with PCOS who do not intend to conceive, it is recommended to use low-doses COCs with anti-androgen progestin (cyproterone acetate, drospirenone, or desogestrel) for the management of hirsutism (Grade A, EL 1). Cyproterone acetate has been shown to be more beneficial than other progestins in Indian conditions.
  - Use of direct hair removal methods are recommended along with COCs as fist-line therapy (Grade A, EL 1).
  - If there is no improvement with COCs or COCs are not tolerated, it is recommended to use spironolactone or finasteride (Grade A, EL 2); spironolactone or finasteride are suggested but recommended to stop 6 months before planned pregnancy.
  - In women with PCOS, if menstrual irregularity and hirsutism are diagnosed, low-dose COCs with anti-androgenic activity (CPA, drospirenone, desogestrel) are suggested (Grade A, EL 2). The ideal time to stop hormonal therapy for hyperandrogenism cannot be established with existing evidence (Grade A, EL 4).
  - Risk of thromboembolism with use of COCs can be managed by identifying susceptible patients and/or pausing treatment for 3 months after one year of treatment (Grade A, EL 4).
  - In adolescents/children with hyperandrogenism, obesity and signs of insulin resistance, lifestyle modification is first-line
therapy; metformin is second-line therapy with a wait period of 2 years post-menarche in children (Grade A, EL 4).

- In adolescents with hyperandrogenism, if glucose intolerance is not established by OGTT, metformin should not be started (Grade B, EL 4).
- Due to insufficient evidence, alternative (acupuncture) and complementary therapeutic options (e.g. myoinositol, omega-3 fatty acids) are not recommended for the management of hyperandrogenism (Grade B, EL 4).

**Acne**

- In adults and adolescents with PCOS and acne, it is suggested to use topical medication along with pharmacological interventions based on the clinical presentation of acne as early as possible, in consultation with dermatologist (Grade A, EL 4).
- In adults with PCOS, it is suggested to use oral contraceptives (cyproterone acetate, drospirenone, or desogestrel as progesterin component) as first-line therapy for management of all types of acne lesions (Grade A, EL 1). Cyproterone acetate has been shown to be more beneficial than other progestins in Indian conditions.
- In adolescents with PCOS and acne, it is suggested to use oral contraceptives (cyproterone acetate, drospirenone, or desogestrel as progesterin component) based on the clinical presentation of acne, in consultation with dermatologist (Grade A, EL 2).

**Alopecia**

- In women with PCOS presenting with alopecia, COCs and androgen blockers are recommended as first-line therapy (Grade B, EL 3).

### EVALUATION AND MANAGEMENT OF ASSOCIATED MORBID CONDITIONS

A number of short- and long-term health problems are associated with PCOS. These include short-term psychosocial problems and long-term problems such as T2DM, obesity, CVD, sleep-disordered breathing and increased risk of endometrial cancer (EC) as well as short-term problems such as impaired fertility, complications during pregnancy.

**PSYCHOSOCIAL MANAGEMENT**

PCOS is strongly associated with reproductive and metabolic implications affecting patients’ psychological functioning and satisfaction with life. Psychological implications entail challenges in depression, physical appearance/feminine identity, eating habits and psychosexual dysfunction with significant impact on quality of life (QoL).

#### Depression

**Current evidence**

Increased rate of depressive symptoms compared to non-BMI matched controls with prevalence ranging from 28 to 64% (for depression) and 34 to 57% (for anxiety) have been reported in women with PCOS. Also, a lower health related QoL and increased risk of mental depression are reported in women with PCOS. In Indian women a 54% prevalence of depression (GHQ28 score ≥ 8) was reported, of whom 72% were obese, 70% had hirsutism, 61% had acne and 56% were infertile indicating a considerable effect on QoL of these women. The Patient Health Questionnaire 9 (PHQ-9) can be used to measure the severity of depression whereas the generic Short Form-36 (SF-36) and disease-specific polycystic ovary syndrome questionnaire (PCOSQ) are used to assess the health related QoL in women with PCOS.

**Existing guidelines**

The clinical practice guidelines from Endocrine society and PCOS Australian alliance suggest screening all women with PCOS for depression and anxiety by history and, if identified, provide appropriate referral and/or treatment.

**Recommendations on management of depression in PCOS**

- In adults and adolescents with PCOS, it is recommended to routinely screen for depression and anxiety with appropriate psychological instruments (Grade B, EL 3).
- In patients with PCOS evaluated with depression and/or anxiety, psychological counseling by an appropriate professional is suggested, based on severity of disease (Grade B, EL 4).

**Other psychosocial dysfunctions**

**Current evidence**

In patients with PCOS, negative self-image coupled with lower self-esteem owing to their physical appearance that significantly

### Appendix Table 4. Patient health questionnaire 9-scale for severity of depression

<table>
<thead>
<tr>
<th>Name:</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Over the last 2 weeks, how often you have been bothered by any of the following problems</strong></td>
<td><strong>Not at all</strong></td>
</tr>
<tr>
<td><strong>Little interest or pleasure in doing things</strong></td>
<td>0</td>
</tr>
<tr>
<td><strong>Feeling down, depressed, or hopeless</strong></td>
<td>0</td>
</tr>
<tr>
<td><strong>Trouble falling or staying asleep, or sleeping too much</strong></td>
<td>0</td>
</tr>
<tr>
<td><strong>Feeling tired or having little energy</strong></td>
<td>0</td>
</tr>
<tr>
<td><strong>Poor appetite or overeating</strong></td>
<td>0</td>
</tr>
<tr>
<td><strong>Feeling bad about yourself- or that you are a failure or have let yourself or your family down</strong></td>
<td>0</td>
</tr>
<tr>
<td><strong>Trouble concentrating on things such as reading the newspaper or watching television</strong></td>
<td>0</td>
</tr>
<tr>
<td><strong>Moving or speaking slowly that other people could have noticed?</strong></td>
<td>0</td>
</tr>
<tr>
<td><strong>Thoughts that you would be better off dead or hurting yourself in some way</strong></td>
<td>0</td>
</tr>
</tbody>
</table>

Total

Source: Kroenke et al. 2001
Malik, et al.: A Consensus Evidence-based Good Clinical Practice Recommendations

Fertility Science and Research / Jan-Jun 2014 / Vol 1 | Issue 1

impacts the mood and QoL [121]. Similarly, significantly more patients with PCOS compared to community controls reported eating disorders (12% vs. 4%) and/or social phobia (27% vs. 2%) [122], which may cause medical, psychological, social and occupational difficulties [123,124]. Physical manifestations of PCOS such as hirsutism, obesity, MI and infertility can have a negative effect on the patients’ sexual life [125].

Existing guidelines

The clinical practice guidelines from PCOS Australian alliance, Australia [30] suggest the screening and assessment of patient’s psychosocial dysfunctions and if identified, offer appropriate treatment.

6.1.2 Recommendations on management of other psychosocial dysfunctions in PCOS

- If a woman with PCOS is positive on screening for any psychosocial dysfunction, the practitioner should perform a more detailed clinical interview (Grade B EL 4).

Appendix Table 5. Polycystic ovary syndrome questionnaire

<table>
<thead>
<tr>
<th>Weight</th>
<th>A Severe Problem</th>
<th>A Major Problem</th>
<th>A Moderate Problem</th>
<th>Some Problem</th>
<th>A Little Problem</th>
<th>Hardly Any Problem</th>
<th>No Problem</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concerned about being overweight?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Had trouble dealing with weight?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Felt frustration trying to lose weight?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feel like you are not sexy because of being overweight?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infertility problems</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concerned with infertility problems?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Felt afraid of not having children?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feel a lack of control over the situation with PCOS?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feel sad because of infertility problems?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emotions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depressed having PCOS?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Easily tired?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moody as a result of having PCOS?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Had low self-esteem having PCOS?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Felt frightened of getting cancer?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Worried about having PCOS?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-conscious as a result of having PCOS?*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*During the past two weeks, how much of the time have you felt? **In relation to your last menstruation, how much the following issues were a problem for you? Source: Cronin et al. 1998

Appendix Table 6. Risk factors for cardiovascular disease and lipid target values* in women with polycystic ovary syndrome

<table>
<thead>
<tr>
<th>PCOS Risk factors</th>
<th>At risk</th>
<th>At high risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk factors</td>
<td>Obesity, cigarette smoking, hypertension, dyslipidemia, subclinical vascular disease, Metabolic syndrome, T2DM, IGT; family history of premature CVD (55 years of age in male relative, 65 years of age in female relative)</td>
<td>overt vascular or renal disease, cardiovascular diseases</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>≥88*, ≥80**</td>
<td>80-100</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>&gt;30***</td>
<td>100-130</td>
</tr>
<tr>
<td>BP, mmHg</td>
<td>Systolic=120; Diastolic=80</td>
<td>70-100</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>&lt;150</td>
<td>100-130</td>
</tr>
<tr>
<td>LDL target, mg/dL</td>
<td>≤130</td>
<td>70-100</td>
</tr>
<tr>
<td>Non-HDL target, mg/dL</td>
<td>≤160</td>
<td>100-130</td>
</tr>
</tbody>
</table>

*Values are based on at least 12-h fasting lipid determinations. Predictive utility for CVD events based on non-fasting lipoprotein lipid values has not yet been clearly validated. *For Caucasian/African-American women, **For Hispanic, Native American, Asian (East and South), and European women, ***A 2-h post 75-g oral glucose challenge be performed in PCOS women, or alternatively in lean PCOS women with advanced age (>40 year), personal history of gestational diabetes, or family history of T2DM. PCOS: Polycystic ovary syndrome, IGT: Impaired glucose tolerance, CVD: Cardiovascular disease, T2DM: Type 2 diabetes mellitus, BMI: Body mass index, BP: Blood pressure, LDL: Low-density lipoprotein, HDL: High-density lipoprotein, Source: Adapted from Wild et al. 2010

 impacts the mood and QoL [121] are observed. Similarly, significantly more patients with PCOS compared to community controls reported eating disorders (12% vs. 4%) and/or social phobia (27% vs. 2%) [122], which may cause medical, psychological, social and occupational difficulties [123,124]. Physical manifestations of PCOS such as hirsutism, obesity, MI and infertility can have a negative effect on the patients’ sexual life [125].

Existing guidelines

The clinical practice guidelines from PCOS Australian alliance, Australia [30] suggest the screening and assessment of patient’s psychosocial dysfunctions and if identified, offer appropriate treatment.

6.1.2 Recommendations on management of other psychosocial dysfunctions in PCOS

- If a woman with PCOS is positive on screening for any psychosocial dysfunction, the practitioner should perform a more detailed clinical interview (Grade B EL 4).
• In those evaluated with any psychosocial dysfunction, appropriate treatment for improvement of quality of life is suggested (Grade B, EL 4).

Type 2 diabetes mellitus

Current evidence

Diagnosis of PCOS confers a 5- to 10- fold increased risk of developing T2DM,[126-128] IR, resulting in hyperinsulinemia also plays a role in the pathogenesis of reproductive disorders in women with PCOS.[126,129] The prevalence of glucose intolerance in Indian women with PCOS[93] was reported as 16.3% (adults 19.1%, adolescents 9.7%).[67]

Due to the risk of IGT, T2DM, and IR in PCOS, evaluation of abnormalities in glucose intolerance at periodic intervals is essential.[9,31,82] A 75-gm (OGTT with 75 g– oral glucose load) has been recommended over measuring glycated hemoglobin (HbA1c) for the detection of T2DM[40] and fasting glucose[67] for assessment of IGT.[3] An observational study from India reported '2-hour post-glucose insulin levels' as a better indicator of IR in women with PCOS than other techniques.[131]

Lifestyle modification with exercise and diet are the first-line treatment for weight management and impaired IGT in women with PCOS. Due to the inherent IR in this condition, oral anti-diabetics (OADs) particularly insulin sensitizers such as metformin are the most promising pharmacological option.[132] However, an early referral to specialist diabetological care is recommended for timely management of diabetes and its complications. Metformin alone or in combination with low-dose spironolactone/ clopimide has demonstrated significant alleviation of not only the MI but also glucose tolerance and insulin sensitivity in patients with PCOS.[81,133]

Hyperthyroidism

Evidence from India reported high prevalence of thyroid disorders (higher mean TSH level 4.547 ± 2.66 vs. 2.67 ± 3.11, p < 0.05) in women with PCOS than those without.[114] Metformin can lower TSH levels in women with PCOS and hypothyroidism. Metformin (1500 mg/day) was shown to significantly decrease (mean ± SD) TSH levels (7.78 ± 1.74 at baseline to 6.14 ± 2.47, p < 0.001) over placebo in overweight women with PCOS and hypothyroidism after 6 months of treatment, with no significant change in free T3 and free T4 levels throughout the study.[133]

Existing guidelines

The clinical practice guidelines from Endocrine society, USA,[29] PCOS Australia alliance, Australia,[30] RCOG,[31] and AE-PCOS society[136] recommend screening women with PCOS for impaired glucose tolerance and T2DM using a 75 gm oral glucose tolerance test; an HbA1c test should be used only when an OGTT is not feasible (Grade A, EL 2).

• In women with PCOS who have impaired glucose tolerance or T2DM, it is recommended to use metformin alone, or in combination with oral contraceptives (Grade A, EL 1).

• Early referral to specialist diabetological care is recommended for timely management of diabetes and its complications (Grade A, EL 4)

Cardiovascular risk

Women with PCOS often have cardiovascular disease risk factors. The AE-PCOS society recommends all women with PCOS to be assessed for CVD risk; to test for BMI, waist circumference and blood pressure at each clinical visit.[116,117] In women diagnosed with PCOS, a complete fasting lipid profile as well as OGTT (if BMI > 30 kg/m², age > 40 years, personal history of GDM, or family history of T2DM) are recommended.[136] A stratification of risk factors for CVD in women with PCOS given by AE-PCOS society is presented in Appendix Table 6.

In India a 37.5% prevalence of obesity (BMI > 27.5 kg/m²);[64] high levels of BP (SBP/DBP > 120/ 80 mm of Hg) inform prospective[138] and cross sectional[139] studies were reported in women with PCOS. Further, increased LDL-C, CVD risk factors, markers of dyslipidemia were noted.[31,139,140] markers of atherosclerosis, flow-mediated dilatation of brachial artery (12.18 ± 2.3% in PCOS vs. 8.3 ± 2.23% in control) and carotid intima media thickness (0.68 ± 0.11 in PCOS vs 0.52 ± 0.02 in control, p = 0.01) were reported in women with PCOS compared to control subjects.[139] Epidemiological data from USA reported a relative risk of 1.53 (95% CI: 1.24; 1.90) for CVD (after adjustment for BMI and potential confounders) in women with very irregular cycles.[141] Therefore, in women with PCOS showing CV risk factors, specialist CV monitoring and care is recommended, irrespective of the severity of their symptoms.

Existing guidelines

The clinical practice guidelines from Endocrine society, USA,[29] PCOS Australia alliance, Australia,[30] RCOG,[31] and AE-PCOS society[136] recommend screening women with PCOS for CV risk factors. The clinical practice guidelines from Endocrine society[28] suggest lifestyle modifications as first-line therapy for CVD and metformin as second line therapy in patients failing to achieve weight reduction with lifestyle modification.[29] The RCOG guidelines[31] suggest hypertension should be treated, but recommended against the use of routine lipid-lowering treatment in women with PCOS and risk of CVD. Consultation with specialists has been recommended by other guidelines for prescribing lipid lowering agents.

Recommendations for the management of cardiovascular risk in PCOS

• It is recommended to screen for CV disease in adult women with PCOS by assessing risk factors: obesity (especially abdominal obesity), smoking, hypertension, dyslipidemia

Fertility Science and Research / Jan-Jun 2014 / Vol 1 | Issue 1
Pregnancy complications

Current evidence

A population-based cohort study among women with PCOS from Sweden observed that PCOS was strongly associated with pre-eclampsia (adjusted OR 1.45, 95% CI: 1.24-1.69), preterm birth (2.21, 1.69 to 2.90), more than double risk of GDM (2.32, 1.88 to 2.88), and birth of large for gestational age infants (1.39, 1.19 to 1.62).\[142\] The results are further confirmed in an independent meta-analysis by Kjerulf.\[144\] Recurrent pregnancy loss (RPL) in women with PCOS is commonly associated with IR,\[144\] hyperhomocysteinemia (HHcy)\[145\] and obesity.\[146\] In a retrospective study on RPL, a significantly higher incidence of HHcy (70.63% vs. 57.26%, p < 0.04) and IR (56.34% vs. 63.3%, p < 0.0001) was observed in women with PCOS compared to controls. Further analysis revealed HHcy as a strong plausible factor for diagnosis of RPL than IR (probability percentage: HHcy = 43.32%, IR = 37.29%). Findings on association of PCOS and GDM are conflicting with respect to BMI. Recent systematic review and meta-analysis in women with PCOS observed a significantly higher risk for development of GDM in PCOS women than those without (OR: 2.89, 95% CI: 1.68-4.98), albeit with significant statistical heterogeneity due to sensitivity analysis (I² = 59.3%).\[147\] An RCT in women with PCOS treated with metformin found no difference in the prevalence of pre-eclampsia (p = 0.18), preterm delivery (p = 0.12), or prevalence of GDM (p = 0.87) compared to controls during pregnancy.\[148\]

A latest meta-analysis of RCTs (n = 5) comparing the effects of metformin with insulin on glycaemic control, maternal and neonatal outcomes in GDM concluded that metformin is comparable with insulin and might be more suitable for women with mild GDM.\[149\] An observational study from India reported significantly higher benefits of using metformin over insulin in the management of GDM and T2DM.\[150\] Although metformin is reported to be comparable with or superior to insulin in terms of glycaemic control and neonatal outcomes, lack of strong evidence on use of metformin in Indian subjects restricts its clinical use.

Existing guidelines

The clinical practice guidelines from Endocrine society, USA recommend pre-conceptual assessment of BMI, BP and OGTT whereas RCOG guidelines recommend screening for GDM before 20 weeks of gestation, in PCOS women requiring ovulation.\[31\] The clinical practice guidelines from Endocrine society and RCOG guidelines\[31\] suggest against the use of metformin as first-line treatment for pregnancy complications in women with PCOS.

Recommendations for the management of pregnancy complications in PCOS

- In women with PCOS planning to have children, it is recommended to screen for markers of obesity, hypertension and IR to reduce the risk of pregnancy-related complications (Grade A, EL 3).
- In women with PCOS who have experienced a miscarriage, it is suggested to assess serum homocysteine levels for identification and treatment of hyperhomocysteinemia mediated repeated pregnancy losses (Grade B, EL 3).
- In women with PCOS, it is recommended not to use metformin therapy only during pregnancy until specific evidence on beneficial effects is demonstrated (Grade B, EL 3).

Endometrial cancer

Current evidence

Long-term studies and meta-analyses have observed an increased risk of development of EC in women with PCOS.\[151-153\] The symptoms, oligo-/amenorrhea, hirsutism, and infertility, as well as risk factors of PCOS, obesity and T2DM, are common to EC.\[154,155\] Evidence for the applicability of transvaginal sonography (TVS) for predicting endometrial hyperplasia has been inconsistent in literature.\[156-158\]

Indian studies on the measurement of endometrial thickness in women with PCOS have routinely used TVS at a cut-off of 4 mm.\[159-161\] In the context of increased risk of EC in PCOS patients with prolonged amenorrhea, abnormal uterine bleeding, obesity and/or diabetes, it is essential to assess endometrial thickness and raise awareness about EC in these women. It has been established that inducing a withdrawal bleed every 3 to 4 months with progestogens can reduce the risk of EC in women with PCOS.\[156\] However, since hyperinsulinemia is the primary cause of endometrial hyperplasia, use of insulin sensitizers can reduce the hyperplasia in these women. Overall, for timely detection and management of EC, it is appropriate to screen for development of cancer at regular intervals with reference to oncological specialist.

Existing guidelines

The clinical practice guidelines from Endocrine society suggest against routine screening for endometrial thickness in women with PCOS. The RCOG guidelines suggest investigating oligomenorrheic women and absence of normal withdrawal bleeds using local protocols such as ultrasound scan, endometrial sampling and/or hysteroscopy and recommend treatment with progestogens to induce a withdrawal bleed at least every 3-4 months.

Recommendations for assessment and management of endometrial cancer in PCOS

- In women with PCOS without abnormal bleeding, routine screening using TVS is not recommended (Grade B, EL 1).
- In women with PCOS with unexpected bleeding and spotting, it is suggested to assess endometrial thickness using TVS and report the same to the physicians (Grade B, EL 4).
• In women with PCOS and risk of endometrial carcinoma, it is suggested to use progestogens every 3-4 months (Grade B, EL 3).
• Regular oncological referrals, for screening at a clinically feasible periodicity, are recommended for timely detection of endometrial cancer (Grade A, EL 4).

Obstructive sleep apnea
Current evidence
Studies have identified a higher incidence of obstructive sleep apnea (OSA) in women with PCOS compared to controls, even after controlling for BMI. Fasting plasma insulin levels and glucose-to-insulin ratios were strongest predictors for OSA. Therefore factors other than obesity may be involved in the high prevalence of OSA in women with PCOS. Interestingly, a decreased likelihood of OSA was reported in adult and post-menopausal women taking hormonal contraceptives. There is a lack of quality evidence on OSA in women with PCOS from India.

Existing guidelines
The clinical practice guidelines from Endocrine society suggest screening all overweight/ obese women with PCOS for symptoms suggestive of OSA and, if identified, diagnosed using polysomnography and referred for appropriate therapy. The RCOG guidelines suggest an enquiry of snoring and daytime fatigue/somnolence in all women with PCOS, and educate about the possible risks of OSA, and, if identified, offer diagnosis and appropriate therapy.

6.6 Recommendations for of obstructive sleep apnea in PCOS
In adult and adolescent women with PCOS, it is suggested to routinely screen for OSA and insomnolence, if symptoms are suggestive of OSA, investigate using polysomnography and refer to appropriate institution for further therapy (Grade B, EL 4).

Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis
Current evidence
Ethnicity, increasing age and characteristics of MS (obesity, hypertension, dyslipidemia and diabetes) are risk factors of non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis (NAFLD/NASH). A 15-60% prevalence of NAFLD is reported in women with PCOS. A cross-sectional, hospital-based study of women with PCOS from India reported a 67%, 31% and 35% prevalence of NASH, NAFLD and MS, respectively.

In the absence of other specific factors, serum markers for liver dysfunction (such as alanine amino transferase) may be used to screen PCOS women with co-existent IR and metabolic risk factors. However, because of low specificity and sensitivity of elevated levels of serum alanine amino transferase, diagnosing NAFLD in these women (PCOS with IR and/or MS) may require non-invasive quantification of fibrosis (ultrasound) and liver biopsy. In view of the potential complications of NAFLD and NASH in women with PCOS having IR and/or MS, early identification and management of NAFLD and MS is essential for overall reduction of effects of MS in PCOS women.

In non-diabetic non-cirrhotic NASH patients treatment with vitamin E (800IU/day) for 96 weeks demonstrated significant improvement in serum aminotransferase levels, hepatic steatosis, and lobular inflammation (early stage features) but not portal inflammation and hepatic fibrosis (more advanced histologic features). However, based on a meta-analysis that showed that RCTs with vitamin E and other antioxidants were heterogeneous (with respect to type and dose of drug, treatment duration and follow-up, population [pediatric versus adult], and implementation of lifestyle intervention) a recent review noted a firm conclusion on the effect of vitamin E on NAFLD cannot be made.

Existing guidelines
The clinical practice guidelines from Endocrine society suggest against routine screening of NAFLD and NASH but provide awareness of their possibility in women with PCOS.

Recommendations for NAFLD and NASH in PCOS
• In adult and adolescent women with PCOS, it is suggested to provide sufficient awareness on symptoms and complications of NAFLD and NASH and carry out appropriate screening in those diagnosed with insulin resistance and/or metabolic syndrome (Grade B, EL 4).
• In patients with PCOS and NASH, treatment with vitamin E is preferred and metformin is not suggested for reduction of metabolic syndrome with specialist inputs from a multidisciplinary team (Grade B, EL 1).

SUMMARY
PCOS is an important emergent public health problem in India that represents a unique trans-generational risk of transmission of a variety of systemic chronic diseases. It has not been possible in contemporary Indian clinical practice to formulate a comprehensive response which is commensurate with the scale of problem that PCOS poses. This has been mainly due to a lack of strong public and academic discourse centered on the proper management of this gargantuan, yet ill-recognized problem. A strong evidentiary foundation is the cornerstone on which the current academic discourse on PCOS must be based. In addressing a key driver that feeds the inertia surrounding PCOS, the current GCPR seek to fundamentally redefine the paradigms of PCOS care in India. The approach of current recommendations is to provide a strong rationale for harnessing the mutual synergies in a modern multidisciplinary clinical setting to deliver quality PCOS care while providing an evidence-based structure to standardize the approach to PCOS management across treatment settings. It is hoped that the current GCPR will fulfill a key role in helping current clinical practices to transition to a comprehensive PCOS care paradigm in India.

ACKNOWLEDGEMENTS
The authors thank Jeevan Scientific Technology Limited, Hyderabad, India for providing editorial assistance in the development of this manuscript.

REFERENCES


with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception. 2010; 82 (2): 139–146.


90. Falsettì L, Ramazzotto F, Rosina B. Efficacy of combined ethinylestradiol (0.035 mg) and cyproterone acetate (2 mg) in acne and hirsutism in women with polycystic ovary syndrome. J. Obstet. Gynecol. 1997; 17 (6): 565-568.
1275–1280.


